EZH2在卵巢癌中的研究进展  

The research progress of EZH2 in ovarian cancer

作　　者：秦琪[1] 熊焱强[1] 李志英[1] 

机构地区：[1]三峡大学仁和医院妇产科,宜昌443000

出　　处：《生命的化学》2016年第4期509-513,共5页Chemistry of Life

基　　金：湖北省卫生计生西医类一般项目(WJ2015MB178);肿瘤微环境与免疫治疗湖北省重点实验室(三峡大学)开放基金(2015KZL06)

摘　　要：果蝇zeste基因增强子人类同源2(enhancer of zeste homolog 2,EZH2)是近年来肿瘤领域研究的热门靶点基因,其在卵巢恶性肿瘤中表达增高,与卵巢癌的发生发展及预后密切相关。EZH2作为一种重要的负性表观遗传调控蛋白,可通过催化组蛋白3赖氨酸27三甲基化(H3K27me3)和调控新型钙黏蛋白分子CD13等影响卵巢细胞的增殖、迁移和侵袭,对EZH2的深入研究将为治疗卵巢恶性肿瘤提供新的分子靶点。本文就该领域的最新研究进展作一简要综述。Zeste Drosophila gene enhancer human homologue 2 （EZH2） is the hotspot target gene in recent years in the field of cancer research, whose expression is increased in ovarian cancer, and it is related to the in- cidence, development and prognosis of ovarian cancer. EZH2 is a kind of important negative apparent genetic regulatory proteins, through catalytic histone 3 lysine acid 27 trimethylation （H3K27me3） and control of new calcium sticky protein molecule CD13 influence ovarian cell proliferation, migration and invasion. In-depth study of EZH2 will provide new molecular targets for the treatment of malignant ovarian tumors. This paper makes a brief summary of the latest research progress in this field.

关 键 词：EZH2 卵巢癌 表观遗传修饰 H3K27me3 CD13 治疗靶点 

分 类 号：R737.31[医药卫生—肿瘤]